GlaxoSmithKline’s upward trajectory faces a £750M knock with Advair copies. What can fill the gap?

Amid a Street-beating fourth-quarter report, GlaxoSmithKline quantified the hit it’s been bracing for: Advair generics. If copycats launch midyear, Glaxo figures its lead drug will lose more than half its U.S. sales. Can its follow-up drugs—including blockbuster-to-be Trelegy—take up the slack?Original Article